Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05696795 · ClinicalTrials.gov registry record · Phase 2
Janus Kinase Inhibition in Sarcoidosis
A Phase 2 study of Sarcoidosis, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05696795: Completed Phase 2 study of Sarcoidosis, sponsored by Yale University.
NCT05696795 is a Phase 2 study of Sarcoidosis that has completed, run by Yale University. The registered enrollment target is 10 participants, below the 2,169-participant average among 21 other Sarcoidosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05696795, a Phase 2 study of Sarcoidosis, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the role of the oral JAK1 inhibitor, abrocitinib 200 mg once daily, for the treatment of patients with moderate to severe cutaneous sarcoidosis.
Primary Outcome
Improvement in the Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI) after 6 months of abrocitinib therapy. CSAMI is a validated clinical scoring tool for cutaneous sarcoidosis activity and severity. Scores range from 0 to 165. Higher score is worse.
Conditions Studied
Interventions
- DRUG Abrocitinib 200 mg
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2025-04-23 |
| Phase | Phase 2 |
What the finished NCT05696795 record still lists
NCT05696795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 2,169-participant average among 21 other Sarcoidosis trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Sarcoidosis appearing as the primary indexed condition, and to 1 intervention - of which Abrocitinib 200 mg is the first listed.
NCT05696795 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05696795 about?
NCT05696795 is a clinical study titled "Janus Kinase Inhibition in Sarcoidosis". The purpose of this study is to investigate the role of the oral JAK1 inhibitor, abrocitinib 200 mg once daily, for the treatment of patients with moderate to severe cutaneous sarcoidosis.
What is the current status of trial NCT05696795?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-06-01. Estimated completion is 2025-04-23.
What conditions does trial NCT05696795 study?
This clinical trial studies the following conditions: Sarcoidosis.
What interventions are being tested in trial NCT05696795?
The interventions under investigation include: Abrocitinib 200 mg (DRUG).
Who is sponsoring clinical trial NCT05696795?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05696795 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05696795's enrollment target sits among peer trials
10 22nd of 21 the lowest of 21 other Sarcoidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
COMPLETED · Phase 2
-
Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
RECRUITING
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
Cardiac Sarcoidosis Randomized Trial
RECRUITING · Phase 3
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
-
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI